Research Triangle Park, North Carolina Clinical Trials

A listing of Research Triangle Park, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 124 clinical trials
A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH

The study includes 52 weeks, double-blind treatment period. Clinic visits will occur at Randomization and every four weeks from Week 4 through Week 52 and through End of Study period. The study includes a post-dosing study visit that will occur 4 weeks after the last dose of study drug. This …

body mass index
type 2 diabetes mellitus
ballooning degeneration
Viking Clinical Site 116
 (8.3 away) Contact site
  • 12 Sep, 2021
  • +96 other locations
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response …

primary tumor
measurable disease
squamous cell carcinoma
metastatic head and neck squamous cell carcinoma
Duke Cancer Center ( Site 0044)
 (8.3 away) Contact site
  • 19 Sep, 2021
  • +150 other locations
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Relapse Free Survival (RFS) in AML patients compared to Best Supportive Care (BSC) when given as maintenance therapy following allogeneic stem cell transplantation (SCT). This study will have 2 parts: Part …

cell transplantation
bone marrow procedure
blast cells
University of North Carolina /ID# 215814
 (9.8 away) Contact site
  • 19 Sep, 2021
  • +236 other locations
Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab and rituximab plus chemotherapy or (2) allogeneic hematopoietic …

blood transfusion
myeloid malignancy
chemotherapy regimen
Duke Cancer Institute (Adults only)
 (8.3 away) Contact site
  • 08 Sep, 2021
  • +78 other locations
A Study Evaluating the Safety Pharmacokinetics (PK) and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

growth factor
bone marrow procedure
primary cancer
treatment regimen
Duke University Medical Center /ID# 123763
 (8.3 away) Contact site
  • 19 Sep, 2021
  • +51 other locations
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

This is a phase II, open label, multi-center, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in combination with immunosuppressive therapy in pediatric patients with previously untreated or relapsed/refractory severe aplastic anemia or recurrent aplastic anemia. All patients will be treated with eltrombopag for the …

aplastic anemia
severe aplastic anemia
horse anti-thymocyte globulin
Novartis Investigative Site
 (8.3 away) Contact site
  • 19 Sep, 2021
  • +78 other locations
JUNIPER: A Phase 2 Study to Evaluate the Safety Biological Activity and PK of ND-L02-s0201 in Subjects With IPF

A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

carbon monoxide
diffusion capacity of the lung for carbon monoxide
forced vital capacity
Duke University Hospital
 (9.5 away) Contact site
  • 08 Sep, 2021
  • +38 other locations
Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer

This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer and their families.

lung carcinoma
primary malignant neoplasm
lung cancer
University of North Carolina at Chapel Hill
 (9.8 away) Contact site
  • 19 Sep, 2021
  • +18 other locations
A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

bone scan
serum testosterone
luteinizing hormone-releasing hormone agonist
platelet count
University of North Carolina
 (9.8 away) Contact site
  • 19 Sep, 2021
  • +54 other locations
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that selexipag could benefit to patients with CTEPH. This study aims …

pulmonary arterial hypertension
Duke University Medical Center
 (8.5 away) Contact site
  • 09 Sep, 2021
  • +288 other locations